FDA's Ultra-Fast Drug Review Program Raises Concerns Over Transparency and Ethics
A House lawmaker has raised new questions about a Food and Drug Administration program that aims to drastically shorten the review of certain drugs, citing a lack of transparency and potential ethics issues. Rep. Jake Auchincloss (D-MA) wrote a letter to the agency expressing concerns that senior officials involved in the effort are not complying with federal ethics rules.
The Commissioner's National Priority Voucher program is designed to expedite reviews for new medicines that support "national interests." However, Auchincloss claims that details about the program have been shrouded in secrecy, despite multiple congressional inquiries. The agency has failed to respond to requests for information, and it remains unclear whether Congress gave its approval for the plan.
Auchincloss's letter highlights the lack of transparency surrounding the program, which has raised concerns among lawmakers and industry officials that decision-making is being taken away from agency scientists and into the hands of political appointees. The lawmaker also questions the FDA's authority to establish the voucher program without congressional action.
The program has been at the center of controversy over potential conflicts of interest among senior FDA officials who vote on which drugs receive priority vouchers. Eight officials, including Deputy FDA Commissioner Sara Brenner and Dr. Vinay Prasad, who oversees vaccines, are not required to disclose their financial interests or investments, raising concerns about potential conflicts of interest.
The FDA has stressed that final approval decisions continue to be made by drug center staffers, but Auchincloss's letter suggests that the agency may have overstepped its authority in establishing the program. Several senior FDA officials have declined to sign off on drug approvals due to legal concerns.
As the debate surrounding the program continues, lawmakers are seeking answers about its legality and the potential impact on public health. The FDA has yet to respond to questions from Congress, leaving many to wonder about the true nature of this ultra-fast review program.
A House lawmaker has raised new questions about a Food and Drug Administration program that aims to drastically shorten the review of certain drugs, citing a lack of transparency and potential ethics issues. Rep. Jake Auchincloss (D-MA) wrote a letter to the agency expressing concerns that senior officials involved in the effort are not complying with federal ethics rules.
The Commissioner's National Priority Voucher program is designed to expedite reviews for new medicines that support "national interests." However, Auchincloss claims that details about the program have been shrouded in secrecy, despite multiple congressional inquiries. The agency has failed to respond to requests for information, and it remains unclear whether Congress gave its approval for the plan.
Auchincloss's letter highlights the lack of transparency surrounding the program, which has raised concerns among lawmakers and industry officials that decision-making is being taken away from agency scientists and into the hands of political appointees. The lawmaker also questions the FDA's authority to establish the voucher program without congressional action.
The program has been at the center of controversy over potential conflicts of interest among senior FDA officials who vote on which drugs receive priority vouchers. Eight officials, including Deputy FDA Commissioner Sara Brenner and Dr. Vinay Prasad, who oversees vaccines, are not required to disclose their financial interests or investments, raising concerns about potential conflicts of interest.
The FDA has stressed that final approval decisions continue to be made by drug center staffers, but Auchincloss's letter suggests that the agency may have overstepped its authority in establishing the program. Several senior FDA officials have declined to sign off on drug approvals due to legal concerns.
As the debate surrounding the program continues, lawmakers are seeking answers about its legality and the potential impact on public health. The FDA has yet to respond to questions from Congress, leaving many to wonder about the true nature of this ultra-fast review program.